PDE5 Inhibitor for Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Alzheimer Disease
Interventions
DRUG

tadalafil

Once daily dose of Tadalafil will be commenced at 10 mg for 2 weeks, followed by an increase to 20 mg for another 2 weeks and finally increased to 40 mg.

DRUG

Placebo

Matched Placebo will be taken once daily.

All Listed Sponsors
lead

Imperial College London

OTHER

NCT07172815 - PDE5 Inhibitor for Alzheimer's Disease | Biotech Hunter | Biotech Hunter